Hepatitis C virus genotypes in injecting drug users from Romania

• Authors: Camelia Sultana , Codruta Vagu , Aura Temereanca , Camelia Grancea , Josefina Slobozeanu , Simona Ruta
• Languages of publication: EN

Abstracts

EN

Due to the increasing number of infections related to injecting drug use, both the pattern of hepatitis C virus (HCV) transmission, and the circulating genotypes in Europe have changed. As there are little available data in this respect for Romania, the aim of our study was a preliminary analysis of the distribution of HCV genotypes circulating among injecting drug users (IDUs). Of the 45 IDUs evaluated (86.7% men, mean age − 27.6 ± 3.7 years, mean age at first drug use − 17.5 ± 3.9 years), 88.9% presented anti-HCV antibodies, with higher rates in those with an injecting history of more than 10 years; 57.8% of the subjects had detectable HCV viral load. Only 6.7% had markers of chronic hepatitis B infection, and none had anti-HIV antibodies. While HCV subtype 1b is still prevalent (in 50% of the viraemic subjects), other subtypes begin to emerge, especially in younger patients (1a - in 23.1%, 4 - in 11.5%, 3a - in 7.7% of the cases). These data indicate the possibility of major shifts in the distribution of the dominant subtype, underlining the need for close surveillance of HCV infections in IDUs, who can act as a bridging group toward the general population.

Keywords

EN

HCV prevalence; Romania; Injecting drug users; HCV genotypes

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2011
• Volume: 6
• Issue: 5
• Pages: 672-678

Dates

published

1 - 10 - 2011

online

9 - 8 - 2011

Contributors

author

Camelia Sultana

author

Codruta Vagu

• Emergent Diseases Department, Stefan S. Nicolau Institute of Virology, 285 Mihai Bravu Bvd, 030304, Bucharest, Romania

author

Aura Temereanca

author

Camelia Grancea

• Emergent Diseases Department, Stefan S. Nicolau Institute of Virology, 285 Mihai Bravu Bvd, 030304, Bucharest, Romania

author

Josefina Slobozeanu

• Center for Integrated Assistance for Addicts CAIA Pantelimon, 255 Pantelimon Road, 030084, Bucharest, Romania

author

Simona Ruta

References

• [1] European Centre for Disease Prevention and Control, Surveillance and Prevention of Hepatitis B and C in Europe, ECDC, Stockholm, 2010
• [2] European Centre for Disease Prevention and Control, Annual Epidemiological Report on Communicable Diseases in Europe 2010, ECDC, Stockholm, 2010
• [3] Esteban J.I., Sauleda S., Quer J., The changing epidemiology of hepatitis C virus infection in Europe, J. Hepatol., 2008, 48, 148–162 http://dx.doi.org/10.1016/j.jhep.2007.07.033[Crossref]
• [4] European Monitoring Centre for Drugs and Drug Addiction, Annual report on the state of the drugs problem in Europe, EMCDDA, Lisbon, 2010
• [5] Gheorghe L., Csiki I.E., Iacob S., Gheorghe C., Smira R., Regep L., The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006–2008, J. Gastrointestin. Liver Dis., 2010, 19(4), 373–379
• [6] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and National Antidrug Agency from Romania (NAA), National report on drugs situation for Romania, New developments, trends and in-depth information on selected issues, REITOX, Bucharest, 2010
• [7] United Nation on Drugs and Crime, HIV, HBV and HCV behavioral surveillance survey among injecting drug users in Bucharest, Romania, Speed Promotion, Bucharest, 2010
• [8] Rantala M., Van de Laar M., Surveillance and epidemiology of hepatitis B and C in Europe - a review, Eurosurveillance, 2008, http://www.eurosurveillance.org/2008/13/21/reviews/18880
• [9] Grigorescu M., HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C, J. Gastrointestin. Liver Dis., 2009, 18(1), 45–50
• [10] Sutton A.J., Hope V.D., Mathei C., Mravcik V., Sebakova H., Vallejo F., et al., A comparison between the force of infection estimates for bloodborne viruses in injecting drug user populations across the European Union: a modelling study, J. Viral Hepatitis, 2008,15(11), 809–816 [WoS]
• [11] UNGASS, Country Progress Report for Romania, Reporting period: January 2008–December 2009, UNGASS, Romania, 2010
• [12] Bourlière M., Barberin J.M., Rotily M., Guagliardo V., Portal I., Lecomte L., et al., Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users, J. Viral Hepatitis, 2002, 9(1), 62–70 http://dx.doi.org/10.1046/j.1365-2893.2002.00319.x[Crossref]
• [13] Huppe D., Zehnter E., Mauss S., Boker K., Lutz T., Racky S., et al., Epidemiology of chronic hepatitis C in Germany-an analysis of 10,326 patients in hepatitis centres and outpatient units, Z. Gastroenterol., 2008, 46(1), 34–44 http://dx.doi.org/10.1055/s-2007-963691[Crossref]
• [14] Cenci M., De Soccio G., Recchia O., Prevalence of hepatitis C virus (HCV) genotypes in central Italy, Anticancer Res., 2003, 23(6D), 5129–5132
• [15] Nēmecek V., Strunecký O., Genotypic heterogeneity of hepatitis C virus (HCV) from blood donors in the Czech Republic, Epidemiol. Mikrobiol. Imunol., 2009, 58(2), 63–72
• [16] Chlabicz S., Flisiak R., Kowalczuk O., Grzeszczuk A., Pytel-Krolczuk B., Prokopowicz D, et al., Changing HCV genotypes distribution in Poland - Relation to source and time of infection, J.Clin. Virol., 2008, 42(2), 156–159 http://dx.doi.org/10.1016/j.jcv.2008.02.001[WoS][Crossref]
• [17] Svirtlih N., Delic D., Simonovic J., Jevtovic D., Dokic L., Gvozdenovic E., et al., Hepatitis C virus genotypes in Serbia and Montenegro: The prevalence and clinical significance, World J. Gastroenterol., 2007, 13(3), 355–360
• [18] Ahmetagić S., Salkić N., Čičkušić E., Zerem E., Mott-Divković S., Tihić N., Hepatitis C virus genotypes in chronic hepatitis C patients and in first time blood donors in Northeastern Bosnia and Herzegovina, Bosnian Journal of Basic Medical Sciences, 2009, 9(4), 278–282
• [19] Paintsil E., Verevochkin S.V., Dukhovlinova E., Niccolai L., Barbour R., White E., et al., Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection, Addiction., 2009, 104(11), 1881–1890 http://dx.doi.org/10.1111/j.1360-0443.2009.02687.x[Crossref][WoS]
• [20] Tallo T., Norder H., Tefanova V., Krispin T., Schmidt J., Ilmoja M., et al. Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time, J. Med. Virol., 2007, 79, 374–382 http://dx.doi.org/10.1002/jmv.20828[WoS][Crossref]
• [21] Colina R., Casane D., Vasquez S., García-Aguirr L., Chunga A., Romero H., et al., Evidence of intratypic recombination in natural populations of hepatitis C virus, J. Gen. Virol., 2004, 85, 31–37 http://dx.doi.org/10.1099/vir.0.19472-0[Crossref]
• [22] Kalinina O., Norder H., Magnius L.O., Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation, J. Gen. Virol., 2004, 85, 1853–1857 http://dx.doi.org/10.1099/vir.0.79984-0[Crossref]
• [23] Van de Laar T.J., Van der Bij A.K., Prins M., Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J. Infect. Dis., 2007, 196, 230–238 http://dx.doi.org/10.1086/518796[WoS][Crossref]
• [24] Danta M., Brown D., Bhagani S., Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours, AIDS, 2007, 21, 983–991 http://dx.doi.org/10.1097/QAD.0b013e3281053a0c[Crossref][WoS]
• [25] Pitigoi D., Rafila A., Pistol A., Arama V., Molagic V., Streinu-Cercel A., Trends in hepatitis B incidence in Romania, 1989–2005, Eurosurveillance, 2008, 13(1–3), 70–74
• [26] Paintsil E., He H., Peters C., Lindenbach B.D., Heimer R., Survival of Hepatitis C Virus in Syringes: Implication for Transmission among Injection Drug Users, J. Infect. Dis., 2010, 202(7), 984–990 http://dx.doi.org/10.1086/656212[WoS][Crossref]
• [27] Huik K., Sadam M., Karki T., Avi R., Krispin T., Paap P., et al., CCL3L1 Copy Number is a strong genetic determinant of HIV seropositivity in caucasian intravenous drug users, J. Infect. Dis., 2010, 201(5), 730–739 http://dx.doi.org/10.1086/650491[WoS][Crossref]
• [28] Ruta S.M., Matusa R.F., Sultana C., Manolescu L., Kozinetz C.A., Kline M., et al., High prevalence of hepatitis B virus markers in Romanian adolescents with HIV, Med. Gen. Med., 2005, 7, 68–72
• [29] National AIDS Committee, Department for AIDS monitoring from Romania, Statistic data on HIV/ AIDS infection in Romania, CNLAS, Bucharest, 2010 (in Romanian)
• [30] EuroHIV, HIV/AIDS Surveillance in Europe. Midyear report 2007 No.76, French Institute for Public Health Surveillance, Saint-Maurice, 2007
• [31] Shakarishvili A., Dubovskaya L.K., Zohrabyan L.S., St Lawrence J.S., Aral S.O., Dugasheva L.G., et al., Sex work, drug use, HIV infection, and spread of sexually transmitted infections in Moscow, Russian Federation, Lancet, 2005, 366, 57–60 http://dx.doi.org/10.1016/S0140-6736(05)66828-6[Crossref]
• [32] Jabłonowska E., Małolepsza E., Causes of death in HIV-infected patients in the region of Lodz, Poland from 1995 through 2005, Cent. Eur. J. Med., 2009, 4(2), 179–183 http://dx.doi.org/10.2478/s11536-009-0005-x[WoS][Crossref]
• [33] Joint United Nations Programme on HIV/AIDS, The Changing HIV/AIDS Epidemic in Europe and Central Asia, UNAIDS, WHO Library, Geneva, 2004

Identifiers

DOI

10.2478/s11536-011-0073-6